Efficacy and safety of dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid allergic rhinitis

• DOI: 10.3389/fmed.2025.1556769
• Publication Date: 2025-04-16T05:27:03Z
• Authors: Tengfei Tian; Yueguang Li; Guangmei Yuan; Wenxiu Jiang
• Keywords: Dupilumab

To examine the efficacy and safety of dupilumab treatment in moderate-to-severe atopic dermatitis (AD) patients with comorbid allergic rhinitis (AR). A total 26 received subcutaneous every 2 weeks were followed up for 16 weeks. The assessment was evaluated based on clinical parameters 4 weeks, including Eczema Area Severity Index (EASI), Pruritus Numeric Rating Scale (P-NRS), Dermatology Life Quality (DLQI) severity AD symptoms, nasal symptom scores (TNSS), visual analogue scale (VAS) Mini Rhino-conjunctivitis Questionnaire (MiniRQLQ) AR symptoms. serum immunoglobulin E (IgE) eosinophil levels collected at baseline after treatment. Treatment-emergent adverse events (TEAEs) ware conducted to evaluate profile dupilumab. Dupilumab resulted a significant improvement symptoms as demonstrated by reduced EASI, NRS, DLQI, ADCT scores. In addition, had TNSS, VAS MiniRQLQ After treatment, blood count, percentage, IgE significantly decreased when compared values (P < 0.01 both). During period, incidence TEAEs 13.77% (n = 8). most commonly reported injection-site reactions 13, 60.25%). clinically relevant improvements an acceptable profile.